Our Expert Network

  1. Building An ASO For TUBB4A-Related Leukodystrophy (Pt. 1) 7/28/2026

    SynaptixBio CEO Dan Williams explains how the company selected an ASO for TUBB4A leukodystrophy by balancing potency, safety, and translational rigor to advance a rare disease therapy.

  2. Nucleic Acid Ligases: Connecting The Pieces For Sustainable And Scalable Production Of Oligonucleotide Therapeutics 7/27/2026

    Chemoenzymatic ligation could overcome the scalability and sustainability limits of traditional oligonucleotide manufacturing, enabling more efficient RNA drug production.

  3. Location Matters: How The Nuclear Geography Of circRNAs Could Shape The Future Of RNA Therapeutics 7/23/2026

    CircRNA location may be as important as its sequence. Discover how nuclear organization could influence the next generation of RNA therapeutics.

  4. Building The RNA Knowledge Graph: How Better Annotation Is Accelerating Therapeutic Discovery 7/22/2026

    As RNA therapeutics grow more complex, better biological annotation is becoming the foundation for AI-driven discovery, target selection, and smarter drug development.

  5. Soliman Says… 5 Questions Every RNA Platform Must Answer Before Investors Write The Check 7/21/2026

    A practical framework for evaluating whether an RNA company has the science, strategy, scalability, and discipline to become a lasting platform.

  6. Beyond Vaccines: Can RNA Sense Gases? 7/20/2026

    Could RNA sense its environment? A new hypothesis explores how RNA may detect temperature and gases, inspiring smarter, adaptive RNA therapeutics.

  7. Building A Self-Driving Lab For LNP Development 7/20/2026

    With commercially available components, MIT researchers built a platform that accelerates LNP process development, optimization, and autonomous manufacturing research.

  8. Decoding RNA's Circular Decisions: How HNRNPD Shapes circRNA Biogenesis And RNA Fate 7/17/2026

    How do cells decide between circular and linear RNA? New insights into HNRNPD reveal mechanisms that could improve the design of future circRNA therapeutics.

  9. Beyond The m⁷G Cap: How Non-Canonical RNA Capping Could Expand RNA Therapeutics 7/16/2026

    Newly discovered non-canonical RNA caps are reshaping RNA biology and could inspire the next generation of more precise, programmable RNA therapeutics.

  10. Beyond Gene Silencing: Harnessing Regulatory RNAs To Increase Gene Expression In Haploinsufficient Disease 7/16/2026

    Can RNA therapeutics increase — not silence — gene expression? Regulatory RNA-targeting ASOs may redefine treatment for haploinsufficient diseases.